| Consensus guidelines for the detection of immunogenic cell death O Kepp, L Senovilla, I Vitale, E Vacchelli, S Adjemian, P Agostinis, ... Oncoimmunology 3 (9), e955691, 2014 | 857 | 2014 |
| Caloric restriction mimetics enhance anticancer immunosurveillance F Pietrocola, J Pol, E Vacchelli, S Rao, DP Enot, EE Baracco, S Levesque, ... Cancer cell 30 (1), 147-160, 2016 | 522 | 2016 |
| First oncolytic virus approved for melanoma immunotherapy J Pol, G Kroemer, L Galluzzi Oncoimmunology 5 (1), e1115641, 2016 | 363 | 2016 |
| Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy J Pol, E Vacchelli, F Aranda, F Castoldi, A Eggermont, I Cremer, ... Oncoimmunology 4 (4), e1008866, 2015 | 309 | 2015 |
| Crizotinib-induced immunogenic cell death in non-small cell lung cancer P Liu, L Zhao, J Pol, S Levesque, A Petrazzuolo, C Pfirschke, C Engblom, ... Nature communications 10 (1), 1486, 2019 | 249 | 2019 |
| The molecular hallmarks of the serrated pathway in colorectal cancer FDE De Palma, V D’argenio, J Pol, G Kroemer, MC Maiuri, F Salvatore Cancers 11 (7), 1017, 2019 | 222 | 2019 |
| Maraba virus as a potent oncolytic vaccine vector JG Pol, L Zhang, BW Bridle, KB Stephenson, J Rességuier, S Hanson, ... Molecular therapy 22 (2), 420-429, 2014 | 195 | 2014 |
| Antitumor benefits of antiviral immunity: an underappreciated aspect of oncolytic virotherapies S Gujar, JG Pol, Y Kim, PW Lee, G Kroemer Trends in immunology 39 (3), 209-221, 2018 | 189 | 2018 |
| Trial watch: peptide-based vaccines in anticancer therapy L Bezu, O Kepp, G Cerrato, J Pol, J Fucikova, R Spisek, L Zitvogel, ... Oncoimmunology 7 (12), e1511506, 2018 | 169 | 2018 |
| Effects of interleukin-2 in immunostimulation and immunosuppression JG Pol, P Caudana, J Paillet, E Piaggio, G Kroemer The Journal of Experimental Medicine 217 (1), 2020 | 158 | 2020 |
| Trial watch: Oncolytic viruses for cancer therapy J Pol, N Bloy, F Obrist, A Eggermont, J Galon, I Cremer, P Erbs, ... Oncoimmunology 3 (6), e28694, 2014 | 157 | 2014 |
| Trial Watch—Oncolytic viruses and cancer therapy J Pol, A Buqué, F Aranda, N Bloy, I Cremer, A Eggermont, P Erbs, ... Oncoimmunology 5 (2), e1117740, 2016 | 144 | 2016 |
| Trial Watch: Peptide-based anticancer vaccines J Pol, N Bloy, A Buqué, A Eggermont, I Cremer, C Sautes-Fridman, ... Oncoimmunology 4 (4), e974411, 2015 | 143 | 2015 |
| HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy BW Bridle, L Chen, CG Lemay, JS Diallo, J Pol, A Nguyen, A Capretta, ... Molecular Therapy 21 (4), 887-94, 2013 | 130 | 2013 |
| Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy ST Workenhe, G Simmons, JG Pol, BD Lichty, WP Halford, KL Mossman Molecular Therapy 22 (1), 123-131, 2014 | 129 | 2014 |
| Heating it up: Oncolytic viruses make tumors ‘hot’ and suitable for checkpoint blockade immunotherapies S Gujar, JG Pol, G Kroemer OncoImmunology, e1442169, 2018 | 124 | 2018 |
| Metabolic vulnerability of cisplatin‐resistant cancers F Obrist, J Michels, S Durand, A Chery, J Pol, S Levesque, A Joseph, ... The EMBO journal 37 (14), e98597, 2018 | 102 | 2018 |
| Immunogenic stress and death of cancer cells: contribution of antigenicity vs adjuvanticity to immunosurveillance N Bloy, P Garcia, CM Laumont, JM Pitt, A Sistigu, G Stoll, T Yamazaki, ... Immunological reviews 280 (1), 165-174, 2017 | 101 | 2017 |
| Acyl-CoA-binding protein is a lipogenic factor that triggers food intake and obesity JM Bravo-San Pedro, V Sica, I Martins, J Pol, F Loos, MC Maiuri, ... Cell Metabolism 30 (4), 754-767. e9, 2019 | 98 | 2019 |
| Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer A Buqué, N Bloy, M Perez-Lanzón, K Iribarren, J Humeau, JG Pol, ... Nature Communications 11 (1), 3819, 2020 | 91 | 2020 |
Guido KroemerUniversité de Paris Cité, Hôpital Européen George Pompidou - AP-HP, Gustave Roussy Cancer CampusVerified email at inserm.fr
